Burden of near vision loss in China: findings from the Global Burden of Disease Study 2019.


Journal

The British journal of ophthalmology
ISSN: 1468-2079
Titre abrégé: Br J Ophthalmol
Pays: England
ID NLM: 0421041

Informations de publication

Date de publication:
03 2023
Historique:
received: 06 05 2021
accepted: 30 09 2021
pubmed: 18 10 2021
medline: 25 2 2023
entrez: 17 10 2021
Statut: ppublish

Résumé

To investigate the burden of near vision loss (NVL) in China by year, age and gender from 1990 to 2019. We used estimates from the Global Burden of Disease (GBD) 2019 study to report the prevalence and disability-adjusted life-years (DALYs) due to NVL in China. Estimates of crude counts and age-standardised rates per 100 000 population are accompanied by 95% uncertainty intervals (UIs). We summarised the age-specific and sex-specific patterns and trends regarding the burden of NVL in China, compared with seven neighbouring countries. From 1990 to 2019, the all-age number and rate for NVL prevalence and DALYs increased significantly in China (all p<0.001). The age-standardised rate decreased from 7538.1 (95% UI 6946.3 to 8075.1) to 7392.9 (95% UI 6855.8 to 7890.5) per 100 000 population for NVL prevalence (p=0.107), and from 74.9 (95% UI 69.6 to 79.9) to 73.8 (95% UI 70.6 to 80.1) per 100 000 population for DALYs (p=0.388). Women had higher NVL prevalence (t=170.1, p<0.001) and DALYs (t=192.5, p<0.001) than men. Higher disease burden of NVL was observed in the middle-aged and elderly population. The age-standardised prevalence and DALY rate attributable to NVL in China were lower than in India, North Korea, Pakistan (all p<0.001), but higher than Russia, South Korea, Singapore and Japan (all p<0.001). Despite a small decrease in age-standardised prevalence and DALYs due to NVL in China in the past two decades, the existing burden is still considerable and significantly higher compared with neighbouring developed countries. An approach that includes all stakeholders is needed to further reduce this burden.

Identifiants

pubmed: 34656988
pii: bjophthalmol-2021-319603
doi: 10.1136/bjophthalmol-2021-319603
doi:

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

436-441

Informations de copyright

© Author(s) (or their employer(s)) 2023. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: NC declares that he is the Director of Research for Orbis International, a non-governmental organisation working in global eye health.

Auteurs

Guangming Jin (G)

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat- sen University, Guangzhou, China.

Minjie Zou (M)

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat- sen University, Guangzhou, China.

Chi Liu (C)

School of Computer Science, University of Technology Sydney, Sydney, New South Wales, Australia.

Aiming Chen (A)

Department of Pharmacy, Fifth Affiliated Hospital of Sun Yat-sen University, Zhuhai, China.

Yi Sun (Y)

Department of Ophthalmology, Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou, China.

Charlotte Aimee Young (CA)

Department of Ophthalmology, Nanchang University, Nanchang, Jiangxi, China.

Yi Li (Y)

Department of Applied Biology and Chemical Technology, The Hong Kong Polytechnic University, Kowloon, Hong Kong.

Danying Zheng (D)

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat- sen University, Guangzhou, China lh.201205@aliyun.com ncongdon1@gmail.com zhengdyy@163.com.

Nathan Congdon (N)

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat- sen University, Guangzhou, China lh.201205@aliyun.com ncongdon1@gmail.com zhengdyy@163.com.
Centre for Public Health, Royal Victoria Hospital, Queen's University Belfast, Belfast, UK.

Xiaotong Han (X)

State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat- sen University, Guangzhou, China lh.201205@aliyun.com ncongdon1@gmail.com zhengdyy@163.com.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH